[Hyderabad, April 25th, 2025] — The global cancer biomarkers market is projected to grow from USD 18.6 B in 2023 to USD 48.3 Bn by 2031 (12.7% CAGR), according to ClearView Market Insights. This 160% expansion reflects oncology’s shift toward blood-based diagnostics and AI-powered decision tools.

Request Sample @ https://clearviewmarketinsights.com/report-details/global-cancer-biomarkers-market/

Section 1: The Biomarker Revolution

1.1 Liquid Biopsy Tipping Point

  • 2024 Medicare Coverage: Guardant360® is now reimbursed for all solid tumors.
  • Tissue-Free TMB: Foundation Medicine’s assay achieves 95% concordance.

1.2 AI’s Disruptive Role

  • Paige Prostate: Cuts false negatives by 45%.
  • Tempus xF: Matches patients to trials 30% faster.

Section 2: 2024 Market Shifts

2.1 Multi-Cancer Early Detection

  • Galleri®: Detects 50+ cancers at Stage I/II.
  • Freenome: AI integrates protein + DNA + RNA signals.

2.2 Pharma Partnerships

Collaboration

Goal

Impact

Roche + Grail

MCED commercialization

10M tests/year by 2027

BMS + Natera

ctDNA for Opdivo® monitoring

50% trial enrollment boost

Section 3: Future Roadmap

2024-2026:

  • 50% of NSCLC testing shifts to liquid biopsies.
  • AI-pathology adopted in 80% of NCCN centers.

2027-2031:

  • MCED screens 20M patients/year.
  • Epigenetic biomarkers dominate AML/lymphoma.


For more insights, visit https://clearviewmarketinsights.com/

About Clearview Market Insights:

Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.

 

Media contact:

Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369